ENLV
HEALTHCAREEnlivex Therapeutics Ltd
$0.83+0.01 (+1.61%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ENLV Today?
No stock-specific AI insight has been generated for ENLV yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.66$2.10
$0.83
Fundamentals
Market Cap$201M
P/E Ratio0.0
EPS$25.48
Dividend Yield—
Dividend / Share—
ROE1.3%
Profit Margin—
Debt / Equity—
Trading
Volume273K
Avg Volume (10D)—
Shares Outstanding241.0M
ENLV News
20 articles- Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World CongressYahoo Finance·Apr 23, 2026
- H.C. Wainwright Highlight Improved Balance Sheet Supporting Enlivex Ltd. (ENLV) OutlookYahoo Finance·Apr 21, 2026
- Ondo Global Markets Tokenizes Enlivex’s Ordinary SharesYahoo Finance·Apr 8, 2026
- Enlivex Therapeutics Q4 Earnings Call HighlightsMarketbeat·Mar 25, 2026
- Off The Hook Yachts and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVYahoo Finance·Mar 20, 2026
- Enlivex Therapeutics announces new listing of RAIN token on KrakenYahoo Finance·Feb 11, 2026
- RedChip Fintech & DATS Conference Replays Now Available Featuring Public Companies Shaping the Future of Digital FinanceYahoo Finance·Feb 9, 2026
- RedChip Spotlights the Future of Finance at Fintech & Digital Asset Treasury Strategy (DATS) Virtual Investor Conference on February 4Yahoo Finance·Jan 27, 2026
- Enlivex Therapeutics Shares to Trade Exclusively on NasdaqYahoo Finance·Jan 23, 2026
- Nasdaq biotech firm bets $212m on new Arbitrum-based prediction marketDlnews·Nov 25, 2025
- Enlivex Unveils $212M Rain Token DAT Strategy as RAIN Surges Over 120%Coinspeaker·Nov 24, 2025
- BC-Most Active StocksYahoo Finance·Nov 24, 2025
- Microcap Biotech Firm Raises $212M for Prediction Market Token Treasury StrategyCoindesk·Nov 24, 2025
- EXCLUSIVE: Enlivex Raises Over $200 Million To Launch First Public Company Prediction Markets PlayYahoo Finance·Nov 24, 2025
- Enlivex Announces Positive 6-Month Topline Data –Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee OsteoarthritisYahoo Finance·Nov 24, 2025
- Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025Yahoo Finance·Oct 28, 2025
- Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVYahoo Finance·Oct 3, 2025
- D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis ProgramYahoo Finance·Sep 29, 2025
- Enlivex Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVYahoo Finance·Sep 19, 2025
- Will Enlivex Therapeutics (NASDAQ:ENLV) Spend Its Cash Wisely?Yahoo Finance·Sep 14, 2025
All 20 articles loaded
Price Data
Open$0.84
Previous Close$0.82
Day High$0.86
Day Low$0.80
52 Week High$2.10
52 Week Low$0.66
52-Week Range
$0.66$2.10
$0.83
Fundamentals
Market Cap$201M
P/E Ratio0.0
EPS$25.48
Dividend Yield—
Dividend / Share—
ROE1.3%
Profit Margin—
Debt / Equity—
Trading
Volume273K
Avg Volume (10D)—
Shares Outstanding241.0M
About Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd. is a clinical stage immunotherapy company. The company is headquartered in Nes Ziona, Israel.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—